Abstract 4242
Background
HIV screening is recommended at time of cancer diagnosis. Moreover, HBV screening, is recommended during immunotherapy due to its risk of reactivation. Furthermore, HCV screening, before using immunotherapy is justified by the prevalence of dysimmune disorders during HCV infection. The main objective of this survey was to evaluate screening practices for HIV, HBV and HCV in cancer patients.
Methods
A cross-sectional study carried- out across 16 French regions between 25/10/2018 and 31/12/2018, evaluating performance of HIV, HBV and HCV systematic screening at time of cancer diagnosis and/or before immunotherapy. An electronic questionnaire was sent to participants in multidisciplinary concertation meetings.
Results
The responses of 290 participants (including 101 surgeons, 61 organ specialists, 50 oncologists, 30 radiotherapists, 21 hematologists and 13 general practitioners) were analyzed. Of the 16 regions targeted, 8 of them are represented by 160 participants (55%). A systematic screening for HIV, HBV and HCV at time of cancer diagnosis was reported by 59 (20%), 66 (23%) and 63 (22%) respondents, respectively. A screening on a case by case for HIV, HBV and HCV was reported by 113, 103 and 102 respondents, respectively while 117 respondents stated to never prescribe HIV testing (40%), 121, HBV testing (42%) and 125 HCV testing (43%). Before immunotherapy, 122 respondents stated that they were not concerned and 89 routinely screened for HIV (31%), 97 for HBV (33%) and 94 for HCV (32%). A screening on a case by case for HIV, HBV, and HCV was reported by 38, 36 and 34 respondents, respectively while 40 respondents stated to never prescribe HIV testing (14%), 34, HBV testing (12%) and 39, HCV testing (13%).
Conclusions
This survey highlights the insufficiency of HIV, HBV and HCV systematic screening at time of cancer diagnosis and/or before immunotherapy. There is a need to raise awareness about the importance of systematic screening in health care providers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract